The use of topical azelaic acid for common skin disorders other than inflammatory rosacea

Cutis

Volumn 77, Issue 2 SUPPL., 2006, Pages 22-24

  Del Rosso, James Q ^a,b,c,d,e,f  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b CollaGenex Pharmaceuticals Inc ^*  (United States)

^c Galderma Laboratories   (United States)

^d Intendis Inc   (United States)

^e Medicis Pharmaceutical Corporation   (United States)

^f Stiefel Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; DERMATOLOGICAL AGENT; DICARBOXYLIC ACID;

HUMAN; INTRADERMAL DRUG ADMINISTRATION; MELANOSIS; PATHOLOGY; PERIORAL DERMATITIS; REVIEW; ROSACEA; SKIN DISEASE;

ADMINISTRATION, CUTANEOUS; DERMATITIS, PERIORAL; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; HUMANS; MELANOSIS; ROSACEA; SKIN DISEASES;

EID: 33645101550     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Nguyen QH, Bui TP. Azelaic acid pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol. 1995;34:75-84.
2. Bladon PT, Burke BM, Cunliffe WJ, et al. Topical azelaic acid and the treatment of acne: a clinical and laboratory comparison with oral tetracycline. Br J Dermatol. 1986;114:493-499.
3. Fitton A, Goa L. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyper-pigmentary skin disorders. Drugs. 1991;41:780-798.
4. Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283:162-166.
5. Thiboutot D, Thieroff-Ekerdt R, Graupe K, et al. Efficacy and safety of azelaic acid 15% gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
6. Bikowski JB. Utilizing azelaic acid 15% gel in the treatment of erythematotelangiectatic rosacea. Poster presented at: American Academy of Dermatology; July 20-24, 2005; Chicago, Ill. P19.
7. Jansen T. Azelaic acid as a new treatment for perioral dermatitis: results from an open study. Br J Dermatol. 2004;151:933-934.
8. Hermanns JF, Petit L, Pierard-Franchimont C, et al. Assessment of topical hypopigmenting agents on solar lentigines of Asian women. Dermatology. 2002;204:281-286.
9. Duteil L, Ortonne JP. Colorimetric assessment of the effects of azelaic acid on light-induced skin pigmentation. Photodermatol Photoimmunol Photomed. 1992;9:67-71.
10. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13.
11. Pelle MT, Crawford GH, James WD. Rosacea II: therapy. J Am Acad Dermatol. 2004;51:499-512.
12. Elewski BE, Fleischer AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea. Arch Dermatol. 2003;139:1444-1450.
13. Hsu S, Quan LT. Topical antibacterial agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, Pa: WB Saunders; 2001:486-488.
14. Sivayathorn A, Verallo-Rowell V, Graupe K. 20% azelaic acid cream in the topical treatment of melasma: a double-blind comparison with 2% hydroquinone. Eur J Dermatol. 1995;5:680-684.
15. Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh). 1989;143:58-61.
16. Balina LM, Graupe K. The treatment of melasma: 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893-895.
17. Breathnach AS. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. Cutis. 1996;57(suppl 1):36-45.
18. Graupe K, Verallo-Rowell VM, Verallo V, et al. Combined use of 20% azelaic acid and 0.05% tretinoin cream in topical treatment of melasma. J Dermatolog Treat. 1996;7:235-237.
19. Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology. 2002;205:249-254.
20. Griffiths CM, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma: a vehicle-controlled, clinical trial. Br J Dermatol. 1994;129:415-421.
21. Nazzaro-Porro M, Passi S, Picardo M, et al. Beneficial effect of 15% azelaic acid cream on acne vulgaris. Br J Dermatol. 1983;109:45-48.
22. Breathnach AC, Nazzaro-Porro M, Passi S, et al. Azelaic acid therapy in disorders of pigmentation. Clin Dermatol. 1989;7:106-119.
23. Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Clin Ther. 1998;20:960-970.